Carnegie Mellon researchers receive grant

December 09, 2009

PITTSBURGH--Carnegie Mellon University's Yoed Rabin and Kenji Shimada have received a four-year, $1.3 million grant from the National Cancer Institute to develop computerized training tools for cryosurgery, which is the destruction of undesired tissue, such as cancerous tumors and organs, by freezing.

At present, minimally invasive cryosurgery, such as prostate cryosurgery, is performed by inserting cryoprobes -- in the shape of long hypodermic needles with a cooling tip -- into the tumor. Cryoprobes placement and the following process of freezing are monitored by an imaging technique, such as ultrasound or MRI.

Mechanical engineering professors Rabin and Shimada are developing an interactive simulator for the entire cryosurgical procedure, combined with a computerized tutor to evaluate the quality of simulated clinical cases.

"This is a revolutionary concept of enhancing surgical training by practicing a virtual cryosurgical procedure," said Rabin, who is leading this project and is an expert in biothermal technology.

Rabin has been developing cryosurgical devices, research techniques and training methods for the past 18 years.

"While we have already developed rapid computer simulation techniques for cryosurgery and algorithms to help make better cryosurgery planning decisions, the challenge in the current project is to develop an interactive tool, which is capable of evaluating and comparing varying surgical scenarios," Rabin said.

"It is like a video game. With our computerized training system, surgeons will be able to try out various cryoprobe placements without risk, visualize frozen regions with intuitive 3D computer graphics, and benchmark their performance with hundreds of cases stored in a database. It is a motivational and effective way of learning and improving their surgical skills," said Shimada, who is an expert in computational modeling and simulation for product design, engineering analysis and factory automation.

While the developed computerized training tools are potentially applicable to all cryosurgical procedures, the current project is aimed at prostate cancer.

The American Cancer Society estimates that 192,280 new cases of prostate cancer will be diagnosed in the United States in 2009. Prostate cancer is the second leading cause of cancer death in men, exceeded only by lung cancer. One in six men will get prostate cancer during his lifetime, and one in 35 will die of this disease.

Minimally invasive cryosurgery is one of the established applications to treat prostate cancer.

"The combination of traditional training techniques with cost-effective computerized training tools can potentially be of high impact on the quality and cost of the cryosurgical treatment, and I am committed to its development and integration," Rabin said.
-end-
About Carnegie Mellon: Carnegie Mellon (www.cmu.edu) is a private, internationally ranked research university with programs in areas ranging from science, technology and business, to public policy, the humanities and the fine arts. More than 11,000 students in the university's seven schools and colleges benefit from a small student-to-faculty ratio and an education characterized by its focus on creating and implementing solutions for real problems, interdisciplinary collaboration and innovation. A global university, Carnegie Mellon's main campus in the United States is in Pittsburgh, Pa. It has campuses in California's Silicon Valley and Qatar, and programs in Asia, Australia and Europe. The university is in the midst of a $1 billion fundraising campaign, titled "Inspire Innovation: The Campaign for Carnegie Mellon University," which aims to build its endowment, support faculty, students and innovative research, and enhance the physical campus with equipment and facility improvements.

Carnegie Mellon University

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.